US.BMY · Bristol Myers Squibb

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.1287843137254905,
        "turnoverUsdM": 412.2754575,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BMY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 61.0358,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4.3,
      "take_profit_price": 66.9375,
      "target_multiplier": 1.6,
      "technical_strength": 1.38,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.257568627450981,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 53.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 50.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 66.235,
    "ma50": 63.283,
    "close": 63.75,
    "prevClose": 64.41,
    "avgVolume20": 7923743,
    "volumeRatio": 0.82,
    "changePercent": -1.02
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.05778894472361806,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.8108289127079553,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.934114509295624,
      "volat_points": 0,
      "day_range_pct": 0.018509803921568622,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 53.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 80,
        "contribution": 4
      },
      {
        "raw": 10,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 4.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 30.67,
        "contribution": 4.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 18.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 61,
        "contribution": 18.3
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 50.3,
    "details": [
      "基本面分析總分: 4/5分",
      "資金流分析總分: 10/20分",
      "市場環境分析總分: 4.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 18.3/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4,
      "資金流": 10,
      "市場環境": 4.6,
      "情緒分析": 4,
      "技術信號": 18.3,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.6,
          "turnoverUsdM": 412.2754575,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.5,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 3.2,
          "obvPoints": 2.4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BMY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.52749955,
                "ma50": 710.6121986999997,
                "name": "QQQ",
                "close": 708.69,
                "points": 0.4
              },
              "spy": {
                "ma20": 767.5584954500001,
                "ma50": 758.2458016200002,
                "name": "SPY",
                "close": 757.83002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.1287843137254905,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142066251,
                "url": "https://finnhub.io/api/news?id=f821a4097c81405b928122f9b8ec1467191361a9e6a725676fdfae39bd714889",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to its last close.",
                "category": "company",
                "datetime": 1789076702,
                "headline": "Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors"
              },
              {
                "id": 142063381,
                "url": "https://finnhub.io/api/news?id=6e01b05c59628b4ff2dcc86605fe7a7840361eb6b84e1b205c557234aad4d152",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.",
                "category": "company",
                "datetime": 1789062420,
                "headline": "BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?"
              },
              {
                "id": 142050448,
                "url": "https://finnhub.io/api/news?id=3bd4334d3c508539047fb6dc644fa4509be3b787e95bb21bb331eefd2d3bb170",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "BMY clears ChartMill’s Best Dividend Stocks screen with a 4.58% yield, but high payout and falling earnings raise sustainability concerns.",
                "category": "company",
                "datetime": 1789030256,
                "headline": "Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question"
              },
              {
                "id": 142029881,
                "url": "https://finnhub.io/api/news?id=6e7355750110ec6cc714f5fd02f23dde4c593ccf21d981b2a31b4ed52e5a5871",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently […]",
                "category": "company",
                "datetime": 1788989678,
                "headline": "Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?"
              },
              {
                "id": 142026021,
                "url": "https://finnhub.io/api/news?id=8594abe1497fc9106ab538c18da2afa5b36087b9d3b0a4028a4f1f1878bc3195",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.",
                "category": "company",
                "datetime": 1788966840,
                "headline": "Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?"
              },
              {
                "id": 141510752,
                "url": "https://finnhub.io/api/news?id=8f773fba44f0e7544ca2cbb54343407ebab89f7232589267dad714a725175f2e",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "BMY shows a strong breakout setup: 10/10 technical rating, 9/10 setup score. Rising moving averages and a buy stop at $68.10 make it one to watch.",
                "category": "company",
                "datetime": 1788604391,
                "headline": "Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup"
              },
              {
                "id": 141464650,
                "url": "https://finnhub.io/api/news?id=70bb4c3c9e836a39e3653498cfd536deac69a7e1b0f43a4312691060ad284681",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.",
                "category": "company",
                "datetime": 1788558303,
                "headline": "Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today"
              },
              {
                "id": 141405350,
                "url": "https://finnhub.io/api/news?id=de1594f724537536ca19ee63ebf071fe4fc45ec11574bf34e50fd61d28fcead4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Despite Bristol-Myers Squibb's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1788449992,
                "headline": "Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?"
              }
            ],
            "raw_source": [
              {
                "id": 142066251,
                "url": "https://finnhub.io/api/news?id=f821a4097c81405b928122f9b8ec1467191361a9e6a725676fdfae39bd714889",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to its last close.",
                "category": "company",
                "datetime": 1789076702,
                "headline": "Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors"
              },
              {
                "id": 142064839,
                "url": "https://finnhub.io/api/news?id=d3e1c3d021cac8d7c584fceec4a97330718f45fbfe390ee1bceaaa151e813902",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Fresh off a regulatory victory for its groundbreaking cancer drug, Revolution Medicines could capture even more of the oncology market.",
                "category": "company",
                "datetime": 1789065600,
                "headline": "Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More."
              },
              {
                "id": 142063381,
                "url": "https://finnhub.io/api/news?id=6e01b05c59628b4ff2dcc86605fe7a7840361eb6b84e1b205c557234aad4d152",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.",
                "category": "company",
                "datetime": 1789062420,
                "headline": "BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?"
              },
              {
                "id": 142063382,
                "url": "https://finnhub.io/api/news?id=6b21a9385e4c2991811576acb36fe32a9b4bd405028d1ef55b707b5ed008ab11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Fresh off a regulatory victory for its groundbreaking cancer drug, Revolution Medicines could capture even more of the oncology market.",
                "category": "company",
                "datetime": 1789060440,
                "headline": "‘Miracle’ Cancer Drug Sets Revolution Medicines Up for More Market Share Gains"
              },
              {
                "id": 142063383,
                "url": "https://finnhub.io/api/news?id=975cba2017d69c30ce859b2ba3e14a66488b8b0beb50da26f10f6b5b7a22f260",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Cytokinetics (CYTK) likely has the upper hand in its patent dispute with Bristol-Myers Squibb (BMY)",
                "category": "company",
                "datetime": 1789056517,
                "headline": "Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says"
              },
              {
                "id": 142061785,
                "url": "https://finnhub.io/api/news?id=319f28aeaea63b63ec1d3933aeb670aebb9c5465de023eaec04e187f46e57e89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.",
                "category": "company",
                "datetime": 1789052702,
                "headline": "Why Has AbbVie Gone Quiet About Humira?"
              },
              {
                "id": 142061864,
                "url": "https://finnhub.io/api/news?id=c282b2ed87af4f65da96e620cab13fb3fbb35e9922e8ba386e2f724c8e629d02",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "HSBC  analyst Rajesh Kumar   maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $60 to $65.",
                "category": "company",
                "datetime": 1789034353,
                "headline": "HSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $65"
              },
              {
                "id": 142050448,
                "url": "https://finnhub.io/api/news?id=3bd4334d3c508539047fb6dc644fa4509be3b787e95bb21bb331eefd2d3bb170",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "BMY clears ChartMill’s Best Dividend Stocks screen with a 4.58% yield, but high payout and falling earnings raise sustainability concerns.",
                "category": "company",
                "datetime": 1789030256,
                "headline": "Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question"
              },
              {
                "id": 142037821,
                "url": "https://finnhub.io/api/news?id=111db1e73b95e44821420ce4a7307dd477cbd22ec124737b00e8ef9d99e156e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.",
                "category": "company",
                "datetime": 1789007538,
                "headline": "Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes"
              },
              {
                "id": 142029881,
                "url": "https://finnhub.io/api/news?id=6e7355750110ec6cc714f5fd02f23dde4c593ccf21d981b2a31b4ed52e5a5871",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently […]",
                "category": "company",
                "datetime": 1788989678,
                "headline": "Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?"
              },
              {
                "id": 142026021,
                "url": "https://finnhub.io/api/news?id=8594abe1497fc9106ab538c18da2afa5b36087b9d3b0a4028a4f1f1878bc3195",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.",
                "category": "company",
                "datetime": 1788966840,
                "headline": "Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?"
              },
              {
                "id": 142024726,
                "url": "https://finnhub.io/api/news?id=c0d76a8928e2fd50eb24afaead652811d0bc0a50082e531baea6c1e64d4b6a32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.",
                "category": "company",
                "datetime": 1788955235,
                "headline": "IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?"
              },
              {
                "id": 142024029,
                "url": "https://finnhub.io/api/news?id=5d724dc0d23a3ebfb1bd6d0a5bbc3f6abe35c00597154f556bba279682e3f9e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "NORTHAMPTON, MA / ACCESS Newswire / September 9, 2026 / Organizations Across Sectors Unite Through the Winn Awards to Advance Better Science For AllPreviously published by the Robert A. Winn Excellence in Clinical Trials Award ProgramA growing coalition of pharmaceutical companies, nonprofit organizations, academic institutions, and clinical research leaders came together through the Robert A.",
                "category": "company",
                "datetime": 1788953340,
                "headline": "National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort"
              },
              {
                "id": 142024031,
                "url": "https://finnhub.io/api/news?id=063037dddb1b85bf3368a02f66a8d588d9c9fa8107f047a9bdc33e346d35cc7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PHILADELPHIA & BOSTON, September 09, 2026--Latus Bio, Inc. (Latus), a biotechnology company engineering gene therapies at scale, today announced the appointments of Donald Hayden, M.B.A., as Chairman and Michael MacLean as independent director and Chair of the Audit Committee of the Latus Board of Directors. Mr. Hayden and Mr. MacLean bring decades of executive leadership experience in driving successful biopharmaceutical companies through key value inflection points and delivering advanced medi",
                "category": "company",
                "datetime": 1788951600,
                "headline": "Latus Bio Appoints Donald Hayden as Chairman of the Board and Michael MacLean as Independent Director and Audit Committee Chair"
              },
              {
                "id": 142006735,
                "url": "https://finnhub.io/api/news?id=93f43e8d7a6488047bd97f1f3f5b6b0aace302de3570d756adf3cb3977279639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Potential extends to earlier-line use, injection-averse patients and new immune-mediated indicationsDublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The \"SOTYKTU Sales Forecast, and Market Size Analysis - 2034\" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of SOTYKTU (deucravacitinib) across approved and potential immune-mediated inflammatory disease indications. The analysis covers the seven major markets (7MM): the United States, Germany, France,",
                "category": "company",
                "datetime": 1788947400,
                "headline": "SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026"
              },
              {
                "id": 141989983,
                "url": "https://finnhub.io/api/news?id=7d0d0a2d383ecb4b94b6d473fd49c6fbe2070ce7fc93b814f798c45ea4a25353",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "CD&R (or the \"Firm\") today announced the appointment of Giovanni Caforio as an Operating Advisor to CD&R funds. The Firm believes his 35-year career in the international biopharmaceutical industry will be invaluable as he supports CD&R funds in identifying and evaluating new investment opportunities within healthcare, as well as working with its portfolio companies globally.",
                "category": "company",
                "datetime": 1788940800,
                "headline": "Giovanni Caforio Appointed Operating Advisor to CD&R Funds"
              },
              {
                "id": 142023862,
                "url": "https://finnhub.io/api/news?id=11fd80725570f8c725693b9b19b81a17ee99e6102f0085df9eb27e7c4d33d9cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.",
                "category": "company",
                "datetime": 1788937200,
                "headline": "A new immuno-oncology play raises $225M for a next-generation drug"
              },
              {
                "id": 141952570,
                "url": "https://finnhub.io/api/news?id=5705e6aac332197632f6883717364f774adac3cf64f03b6da96a17c69f795736",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.",
                "category": "company",
                "datetime": 1788887331,
                "headline": "Is AbbVie Stock Too Reliant On Skyrizi?"
              },
              {
                "id": 141950403,
                "url": "https://finnhub.io/api/news?id=de977806d1f6a3f5226aacf507ea60491cd0a478de36e23fee0a088aa2fcf14b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Collecting $1,000 a month in dividends sounds simple until you realize the capital required shifts every time prices move, and choosing the wrong yield can leave you exposed to a dividend cut when you can least afford it.",
                "category": "company",
                "datetime": 1788880260,
                "headline": "Here’s How Much You Need Invested to Collect $1,000 a Month in Dividends"
              },
              {
                "id": 141955168,
                "url": "https://finnhub.io/api/news?id=354a3a64457ffc02565ac5874663d068bf8ae6d0dab0736fef80a2cab40b1ea1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.",
                "category": "company",
                "datetime": 1788878460,
                "headline": "Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy"
              },
              {
                "id": 141949985,
                "url": "https://finnhub.io/api/news?id=23e22eca29f124149162f38fb98cc7d4fd8a268c0cb690d6bdce0f160f07e68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.",
                "category": "company",
                "datetime": 1788878194,
                "headline": "What Merck Stopped Saying About GARDASIL Should Change What You Watch"
              },
              {
                "id": 141950417,
                "url": "https://finnhub.io/api/news?id=4da9cb88add93435fb30761985c61678f15bf041a6bc9c6ec7cfba6482d7db78",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Social Security's projected 2027 COLA raise sounds promising until you realize retirees feel higher prices months before benefits catch up. Five blue-chip dividend stocks already pay yields that outpace that adjustment, and some have raised their payouts for decades straight.",
                "category": "company",
                "datetime": 1788870027,
                "headline": "Social Security’s 2027 COLA Raise Is the Biggest in 3 Years — But These 5 Dividend Stocks Pay You More"
              },
              {
                "id": 141956122,
                "url": "https://finnhub.io/api/news?id=97dd77234af9ebb51eeba22fdd986eb8f5c878fed4ab2d63990cdaa1e8fde2c0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Rueil-malmaison--France---August-13--202.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Bristol Myers Squibb reported positive Phase 2 results for its arlo-cel therapy, meeting key endpoints for multiple myeloma patients.",
                "category": "company",
                "datetime": 1788866019,
                "headline": "Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients"
              },
              {
                "id": 141950637,
                "url": "https://finnhub.io/api/news?id=731b6c5e68dd8aeb91caf2ed17644c56ecf1e42a7a9706b26ce396bbc55fe995",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., September 08, 2026--Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial",
                "category": "company",
                "datetime": 1788865140,
                "headline": "Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ..."
              },
              {
                "id": 141956123,
                "url": "https://finnhub.io/api/news?id=96a5b74caea66006e472c651805034579ac56ae3ad200ada8a95836edfbd2691",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate in this heavily pretreated patient population who have been exposed to a prior BCMA-targeted therapyQUINTESSENTIAL",
                "category": "company",
                "datetime": 1788850908,
                "headline": "Bristol Myers Squibb Reports Phase 2 Results From Registrational QUINTESSENTIAL Trial Of Arlocabtagene Autoleucel In Quadruple-Class Exposed RRMM Patients; Trial Met Primary Endpoint Of Overall Response Rate And Key Secondary Endpoint Of Complete Response Rate"
              },
              {
                "id": 141771129,
                "url": "https://finnhub.io/api/news?id=8d4ddd4505d0a2c0a565fc6aa50cad54667e4793873643445d02cbd7344ed953",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.",
                "category": "company",
                "datetime": 1788800445,
                "headline": "Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now"
              },
              {
                "id": 141588073,
                "url": "https://finnhub.io/api/news?id=48b74053277caa2f5fc954cf5a1549051ca2d8f182c010e0532f07651e937caf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "On August 13, Atrium Therapeutics (NASDAQ:RNA) reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts. The company disclosed FDA clearance of its IND application for ATR 1072 and the launch of Corventis, its first Phase 1/2 trial and the first study anywhere testing a disease-modifying […]",
                "category": "company",
                "datetime": 1788691442,
                "headline": "Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real"
              },
              {
                "id": 141510752,
                "url": "https://finnhub.io/api/news?id=8f773fba44f0e7544ca2cbb54343407ebab89f7232589267dad714a725175f2e",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "BMY shows a strong breakout setup: 10/10 technical rating, 9/10 setup score. Rising moving averages and a buy stop at $68.10 make it one to watch.",
                "category": "company",
                "datetime": 1788604391,
                "headline": "Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup"
              },
              {
                "id": 141519412,
                "url": "https://finnhub.io/api/news?id=6af93749a5ad16862681beb37392c6dbbeea357e33f9580e3c70c35e1ac295aa",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/639990738/image_639990738.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Bristol Myers Squibb's aggressive M&A and in-house R&D efforts have driven the portfolio renewal cadence and ongoing valuation re-rating. Click for more on BMY.",
                "category": "company",
                "datetime": 1788600504,
                "headline": "Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum"
              },
              {
                "id": 141464650,
                "url": "https://finnhub.io/api/news?id=70bb4c3c9e836a39e3653498cfd536deac69a7e1b0f43a4312691060ad284681",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.",
                "category": "company",
                "datetime": 1788558303,
                "headline": "Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today"
              },
              {
                "id": 141455206,
                "url": "https://finnhub.io/api/news?id=46008aa3897fb677a8af52c36fef7934feeddbea4974aa4a9324d40d2d3fa952",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and",
                "category": "company",
                "datetime": 1788551323,
                "headline": "Sector Update: Healthcare Stocks Decline Late Afternoon"
              },
              {
                "id": 141446802,
                "url": "https://finnhub.io/api/news?id=c0f942183fae38ee06ed79bbe8fc8646f128780b439a91f430d200e429947d94",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H",
                "category": "company",
                "datetime": 1788543665,
                "headline": "Sector Update: Healthcare Stocks Decline Friday Afternoon"
              },
              {
                "id": 141449962,
                "url": "https://finnhub.io/api/news?id=d153250c15bd81ad13b67c1c078e93d454b22ba333de2be0cd15c2ad6f3c0dd9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/04/Gene-Therapy-For-Cancer-Treatment-Concep.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.",
                "category": "company",
                "datetime": 1788521599,
                "headline": "A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths"
              },
              {
                "id": 141425668,
                "url": "https://finnhub.io/api/news?id=47c4b2ed2bec38e175d04009665aa290eda845b05591564bb0fb1d56c72fc776",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) has told regulators, researchers and patient groups in early June that it",
                "category": "company",
                "datetime": 1788516629,
                "headline": "Market Chatter: Bristol Myers Squibb Paused Zola-Cel Trials Over Safety Concerns"
              },
              {
                "id": 141428557,
                "url": "https://finnhub.io/api/news?id=2c936dd7ab91688beb9ce6da968db548fae82c3c793c1a2644cb30d80a20c6c1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2235602110/image_2235602110.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) stock: Strong Buy at 51% sector discount.",
                "category": "company",
                "datetime": 1788514558,
                "headline": "Bristol Myers Squibb: Still Cheap, Despite What The Chart Says"
              },
              {
                "id": 141419536,
                "url": "https://finnhub.io/api/news?id=a2942230b861cfeb31ee86052445c0ff49d003fd707bfd6531e98eba172a935a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2263099480/image_2263099480.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Bristol Myers Squibb's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting total revenue growth. See why BMY stock is a Buy.",
                "category": "company",
                "datetime": 1788506143,
                "headline": "Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price"
              },
              {
                "id": 141401562,
                "url": "https://finnhub.io/api/news?id=1f94100c220d7a64393c01745fc80348758aa2c70eaf3e505da0a90106a9fa2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.",
                "category": "company",
                "datetime": 1788455269,
                "headline": "Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?"
              },
              {
                "id": 141401623,
                "url": "https://finnhub.io/api/news?id=571938922c53a24695a79bd4b7bcf6cadc277e382964d905e6dd29c162da8113",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.",
                "category": "company",
                "datetime": 1788454800,
                "headline": "Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug"
              },
              {
                "id": 141401563,
                "url": "https://finnhub.io/api/news?id=50bde06ec4383c3e8fc1744e10def00da142de1f05932785daae894c39691680",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.",
                "category": "company",
                "datetime": 1788454466,
                "headline": "ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?"
              },
              {
                "id": 141405350,
                "url": "https://finnhub.io/api/news?id=de1594f724537536ca19ee63ebf071fe4fc45ec11574bf34e50fd61d28fcead4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Despite Bristol-Myers Squibb's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1788449992,
                "headline": "Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?"
              },
              {
                "id": 141400446,
                "url": "https://finnhub.io/api/news?id=cdbc5a2b8ff74d546c660d56825b641d1ba0c356cd2404e5938aade463184630",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449413,
                "headline": "Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?"
              },
              {
                "id": 141398201,
                "url": "https://finnhub.io/api/news?id=7a9b4dba5bb25cb824438647b9a5d247c34500fcf42d1f57a257b2902488f1d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Program yields evidence supporting $14.1 million in savings by keeping patients out of the hospitalALEXANDRIA, VA / ACCESS Newswire / September 3, 2026 / Originally published on NCPA.",
                "category": "company",
                "datetime": 1788444000,
                "headline": "Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds"
              },
              {
                "id": 141397416,
                "url": "https://finnhub.io/api/news?id=df0f1022286d048bdd9a82a3e3011888ddbb9f5c783b06f8b7ec5d74057d1fd8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicin",
                "category": "company",
                "datetime": 1788435000,
                "headline": "Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer"
              },
              {
                "id": 141396046,
                "url": "https://finnhub.io/api/news?id=90fc089244dc8485ed1bae6ed814953047aba3ac1c4095ec57995ccba0e89f82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Reviewing prior stock picks is how investors turn experience into valuable feedback.  A recommendation is only a thesis until the market tests it.  Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.",
                "category": "company",
                "datetime": 1788414660,
                "headline": "Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services"
              },
              {
                "id": 141395435,
                "url": "https://finnhub.io/api/news?id=3020ee035c6b5fa5f63c33a9349fbac264d79c0593069f9eb52783c81993f5b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (NYSE:BMY) has paused enrollment in its zola-cel cell therapy trials for autoimmune conditions following emerging safety concerns. The voluntary pause comes after inflammatory side effects were detected during ongoing safety surveillance in the program. The move raises fresh questions around the risk profile of cell-based therapies in autoimmune diseases, as well as the pace of Bristol Myers Squibb's clinical pipeline. For readers interested in more ideas in this corner...",
                "category": "company",
                "datetime": 1788409879,
                "headline": "What Does Bristol Myers Squibb (BMY) Trial Pause Mean For Its Pipeline?"
              },
              {
                "id": 141383190,
                "url": "https://finnhub.io/api/news?id=e182a95e4d7485d608c506c8aecbe8a87907d1a5ebf54cdfe6b70212d13d5007",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The real bet is on what lies beyond this year's performance: a pipeline that could change everything.",
                "category": "company",
                "datetime": 1788382536,
                "headline": "Amgen Stock Signals Its Confidence. The Market Agrees."
              },
              {
                "id": 141379847,
                "url": "https://finnhub.io/api/news?id=79f18174ad181fad00cc082df546211492fa49c31b6547541fd791f75251ab3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.",
                "category": "company",
                "datetime": 1788377400,
                "headline": "Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?"
              },
              {
                "id": 141379513,
                "url": "https://finnhub.io/api/news?id=b83ed80afcb80cbd4652b6ca44f619ec245ce1285bf164a2fe2279ae839bfc54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.",
                "category": "company",
                "datetime": 1788373011,
                "headline": "How Did Merck Stock Beat The Market With Slowing Sales?"
              },
              {
                "id": 141379845,
                "url": "https://finnhub.io/api/news?id=9857fac7df0ba122b7ab45bf81308ca0b990fbf4f3d6509b48b838ae64cba442",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (BMY) is back in focus after presenting long term Camzyos data from the EXPLORER-LTE cohort at the 2026 European Society of Cardiology Congress in Munich. Against this backdrop, Bristol-Myers Squibb’s share price has moved to US$66.92, with a 90 day share price return of 22.3% and a year to date share price return of 25.2%, while the 1 year total shareholder return of 47.9% points to stronger gains once dividends are included. Recent momentum has coincided with strong Q2...",
                "category": "company",
                "datetime": 1788365223,
                "headline": "Bristol Myers Squibb (BMY) Gains On Camzyos Data, Is The Upside Already Priced In?"
              },
              {
                "id": 141379150,
                "url": "https://finnhub.io/api/news?id=fac6b53077cb17d7af20e819aacca07cf62593653b986be157b110f4bed8e7fd",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1788356125,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141379846,
                "url": "https://finnhub.io/api/news?id=afe4f9f5def2846b7cd3e3eed0ea60466a12b33633dc1dbf6d41f78c22339a78",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.",
                "category": "company",
                "datetime": 1788355920,
                "headline": "Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts"
              },
              {
                "id": 141376781,
                "url": "https://finnhub.io/api/news?id=3ee7793f113eb640bae9719676ac3ff7bda91affcde9e0a3c17a72bab4ca4c07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their...",
                "category": "company",
                "datetime": 1788354000,
                "headline": "Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials"
              },
              {
                "id": 141375563,
                "url": "https://finnhub.io/api/news?id=7ab5bcd12588ce30f4b5b5a311969bf31606f4bc2cce08218a7a22084c60a831",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Johnson & Johnson's valuation is above historical averages, already pricing in competent execution. Find out why JNJ stock is a hold.",
                "category": "company",
                "datetime": 1788334184,
                "headline": "Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half"
              },
              {
                "id": 141373338,
                "url": "https://finnhub.io/api/news?id=1d85fa178dacb2e1c48eded9517b42e4492e5fea195b64e93350dbc027ef2ca0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with Bristol-Myers Squibb (NYSE:BMY).",
                "category": "company",
                "datetime": 1788294140,
                "headline": "Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest"
              },
              {
                "id": 141369876,
                "url": "https://finnhub.io/api/news?id=b4b729cd08099e1154aab3a209d040b8a59a911ae8a6cb3d1379f2bf2e6d31aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.",
                "category": "company",
                "datetime": 1788288240,
                "headline": "Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023."
              },
              {
                "id": 141369812,
                "url": "https://finnhub.io/api/news?id=ebd7a8f25257402a2a2fed29a89696330649006797da39c623f94590dbe226b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.",
                "category": "company",
                "datetime": 1788286200,
                "headline": "Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal"
              },
              {
                "id": 141371042,
                "url": "https://finnhub.io/api/news?id=c3d97f2474ba1492f45d4aefcbd682b0faccc912990f1b6b655e1715fbc06cb6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2282553745/image_2282553745.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Alumis Inc. faces high biotech risk after a lupus trial setback, but envudeucitinib TYK2 potential remains. Click for more on ALMS stock.",
                "category": "company",
                "datetime": 1788280574,
                "headline": "Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside"
              },
              {
                "id": 141369873,
                "url": "https://finnhub.io/api/news?id=1bce6207890c6536b7e9eb485b632e6b759d6d03e2e31443e056c8d59c8c4270",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.",
                "category": "company",
                "datetime": 1788276420,
                "headline": "Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough"
              },
              {
                "id": 141360820,
                "url": "https://finnhub.io/api/news?id=1df0df20de7aabb85df09fc4c34c5731bfc6fe40781bd266d3afd73797d03fb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.",
                "category": "company",
                "datetime": 1788202928,
                "headline": "This Popular Healthcare ETF Is Diluting Your Dividend Income"
              },
              {
                "id": 141362139,
                "url": "https://finnhub.io/api/news?id=334ff16fb2f1413e92ef1f691bbdf3a5ee9ba6dfa0ecafb773f753b6ca7f91c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects led Bristol Myers to voluntarily pause its zola-cel program.",
                "category": "company",
                "datetime": 1788201480,
                "headline": "Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns"
              },
              {
                "id": 141362143,
                "url": "https://finnhub.io/api/news?id=9ca2dc520325e202435daf86c34b88f8aeb4b6ba8a8c1f3c7cef6e595b299374",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500’s 12.3% return during that period. This might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1788198864,
                "headline": "3 Reasons to Sell BMY and 1 Stock to Buy Instead"
              },
              {
                "id": 141361469,
                "url": "https://finnhub.io/api/news?id=34e30cd031c810d63415f91661c6455830424a81e544234aa232e3fa4a773e73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1788194343,
                "headline": "Cocrystal Pharma: The Strategic Reset Investors May Be Missing"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141362140,
                "url": "https://finnhub.io/api/news?id=e97b2a46f32c37f55844c94c141bf555c1e96bec9907648b43645032263930ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.",
                "category": "company",
                "datetime": 1788177619,
                "headline": "Jefferies starts biopharma firm Braveheart at Buy after IPO"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141355665,
                "url": "https://finnhub.io/api/news?id=3fb9e5cd83d56af0ff3106385f22de9c49bf39ee4ed9345011f08565e400441a",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in",
                "category": "company",
                "datetime": 1788147649,
                "headline": "Reported Earlier, Bristol Myers Reports Long-Term Camzyos Data Supporting Continued Use In Obstructive HCM"
              },
              {
                "id": 141362133,
                "url": "https://finnhub.io/api/news?id=436efdcbe711a0f6ddfca43b40c1dad10ef68eec29760201884503af8b82c8bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., August 29, 2026--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten)....",
                "category": "company",
                "datetime": 1788019200,
                "headline": "Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026"
              },
              {
                "id": 141351859,
                "url": "https://finnhub.io/api/news?id=7f55208ed921c5798e709369aaccb858071caf982e8dd81a39c805fca5c5aee7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.",
                "category": "company",
                "datetime": 1788017700,
                "headline": "Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors"
              },
              {
                "id": 141362144,
                "url": "https://finnhub.io/api/news?id=55df3c57fa9890a965add1d96a939aeca371acf539b8f1539877ff7205fd8e49",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb has delivered a strong 47.9% return over the past year, yet several valuation checks still frame the stock as cheap relative to an intrinsic value estimate and to market multiples. For investors, the question is whether the current share price reflects a genuine discount or simply the market catching up with earlier pessimism. The 47.9% gain over 1 year highlights how sharply sentiment toward Bristol-Myers Squibb has improved. This can reduce the margin of safety if...",
                "category": "company",
                "datetime": 1788005206,
                "headline": "Bristol Myers Squibb (BMY) Stock Looks Reasonable On Earnings Yet Strong Returns Test Value"
              },
              {
                "id": 141348567,
                "url": "https://finnhub.io/api/news?id=a379190190bdec036257d2748e072424c5c1b755ec036e7bddcd9936dbdcf104",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients. Several approved therapies have delivered strong responses for patients with advanced blood cancers where conventional treatments have failed. It’s no wonder the CAR-T market is expanding rapidly. The global CAR-T therapy market is projected to grow from $2.69 billion in 2022 to […]",
                "category": "company",
                "datetime": 1787974085,
                "headline": "Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb"
              },
              {
                "id": 141362141,
                "url": "https://finnhub.io/api/news?id=d3a233ad9f5bb28e9b5a10b466b1edba3ad286f94aa15528621c639e8403ff1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday.",
                "category": "company",
                "datetime": 1787951157,
                "headline": "Cytokinetics Boasts A First-Ever In Heart Disease — And Shares Drop"
              },
              {
                "id": 141362136,
                "url": "https://finnhub.io/api/news?id=d9056e80fd9cbb58555a4a0f29cbfc2ca1c6dc2c00c4fd7e960960cc760e728f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc. (NASDAQ:RNA) earned a $15 million milestone payment from Bristol-Myers Squibb Company (NYSE:BMY) after delivering a lead RNA compound targeting an undisclosed cardiology indication. The payment stems from a global collaboration eligible to yield Atrium up to […]",
                "category": "company",
                "datetime": 1787949764,
                "headline": "Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?"
              },
              {
                "id": 141348570,
                "url": "https://finnhub.io/api/news?id=4f0e161ba9b9cba902841c73156b0682cae4aa772893993f336979cf573e608d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.",
                "category": "company",
                "datetime": 1787945738,
                "headline": "Can Merck Stock Outrun Its Pipeline?"
              },
              {
                "id": 141339624,
                "url": "https://finnhub.io/api/news?id=44cf81c569d9ca518128cd7ce1b63abb0cdaab2e4a4b7891731afcb9cd738ed8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2291247270/image_2291247270.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. Click for more on BNTX.",
                "category": "company",
                "datetime": 1787933252,
                "headline": "BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More"
              },
              {
                "id": 141362146,
                "url": "https://finnhub.io/api/news?id=1080e54369b4b31bc32dce6d9863d09688d4c17938b85d8187eaec3f63d7d55a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.",
                "category": "company",
                "datetime": 1787921092,
                "headline": "1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges"
              },
              {
                "id": 141362137,
                "url": "https://finnhub.io/api/news?id=6ee8eadf9d92b1904e53af83a55f01493b8a6601d1ba9c95910d273b180cb33d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb Company (NYSE:BMY) has ended its partnership with cell-therapy manufacturer Cellares after determining that Cellares’ Cell Shuttle platform could not meet the requirements needed to manufacture Breyanzi at commercial scale. The partnership, announced in 2024, was valued at up to $380 million and was intended to expand Breyanzi manufacturing capacity across the U.S., Europe, […]",
                "category": "company",
                "datetime": 1787880998,
                "headline": "Bristol-Myers Squibb (BMY)’s Cellares Exit Raises Questions Over Breyanzi Growth"
              },
              {
                "id": 141348581,
                "url": "https://finnhub.io/api/news?id=24458578ebb7cce18a55c1f2c5cdd3519fc2d2bc100626b8dba0bb612a1376ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)’s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson’s Darzalex and dexamethasone. The approval gives BMY another product that could support growth in its oncology business. Iberdomide belongs to a newer class […]",
                "category": "company",
                "datetime": 1787879505,
                "headline": "New FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth Catalyst"
              },
              {
                "id": 141360948,
                "url": "https://finnhub.io/api/news?id=d996d90295ae96f1cb973a3c6604fa866b3ac5806908170eba6410dd94f3ffe8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The oncology franchise that still carries about half of Merck is decelerating while the stock trades near its high.",
                "category": "company",
                "datetime": 1787853707,
                "headline": "Is Merck Stock Reaching A Valuation Ceiling At 6x Sales?"
              },
              {
                "id": 141362149,
                "url": "https://finnhub.io/api/news?id=90f49ef3b7673d7f949bab1cdfe3043d3fe35edbc1810fdcd7e4306777a6bb64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.",
                "category": "company",
                "datetime": 1787853600,
                "headline": "RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer"
              },
              {
                "id": 141362150,
                "url": "https://finnhub.io/api/news?id=d893f623b55a20d2eb13de2e1f2da21b05fa423da8e2863a1ec199f37fa04adf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.",
                "category": "company",
                "datetime": 1787844720,
                "headline": "Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?"
              },
              {
                "id": 141329551,
                "url": "https://finnhub.io/api/news?id=320a5de29203b8e44f2edf5548e3915f957e76feed78625c85f5fe1da7b57b64",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217679967/image_2217679967.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "GSK stock outlook: FDA bepirovirsen Oct 26 decision, Phase 3 OCEAN results, and reaffirmed 2026 guidance. Read here for a detailed investment analysis.",
                "category": "company",
                "datetime": 1787818087,
                "headline": "GSK: Still One Of My Top Healthcare Picks"
              },
              {
                "id": 141322438,
                "url": "https://finnhub.io/api/news?id=5b89a111c396ce77d686a5f752a6b55a41ab4baa4c092d77332afe86e3a63eb8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192991654/image_2192991654.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million. Read why TGTX stock is upgraded to a buy.",
                "category": "company",
                "datetime": 1787731357,
                "headline": "TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)"
              },
              {
                "id": 141319182,
                "url": "https://finnhub.io/api/news?id=d4f42928d4950efafa33a859d71444523fb97bc758e12a18dd6a9b9bebbba798",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "- Reuters ",
                "category": "company",
                "datetime": 1787657800,
                "headline": "Bristol Myers Spokesperson Says Confirm That We Have Ended Our Partnership With Cellares; Determined Cellares-Partnered Cell Shuttle System Could Not Meet Necessary Requirements To Make Commercial Breyanzi"
              },
              {
                "id": 141316607,
                "url": "https://finnhub.io/api/news?id=f649b9f86ef6cc42c05b0e00dc7665d58e101cc4a89153527c255679d3750e45",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/United-States-Treasury-Check-Surrounded-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.",
                "category": "company",
                "datetime": 1787643564,
                "headline": "Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields"
              },
              {
                "id": 141308324,
                "url": "https://finnhub.io/api/news?id=d230e0ece83f4cba236cd869d85db24371c89847d296e0eca3524ccfa078799b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1419068069/image_1419068069.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Sanofi stock faces temporary pressure after Trump’s vaccine order, but trades cheap (9.2x P/E) with raised 2026 guidance. Click for this SNY update.",
                "category": "company",
                "datetime": 1787561537,
                "headline": "Sanofi: Trump's Vaccine Policy Won't Break The Story"
              },
              {
                "id": 141294197,
                "url": "https://finnhub.io/api/news?id=9920479acaf24aa724842791b54472c02592d99d6bd156b129117a03ccd429fb",
                "image": "",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "",
                "category": "company",
                "datetime": 1787400834,
                "headline": "Buy 4 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' August DiviDogs"
              },
              {
                "id": 141278036,
                "url": "https://finnhub.io/api/news?id=c0acd15c497b3e71b58cf211db92a739c50e66b038a6889ccbf7a4e6fd48b035",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant in Houston, part of a larger $40 billion U.S. investment pledge. On the very same day, British regulators cleared Eli Lilly and Company (NYSE:LLY)’s […]",
                "category": "company",
                "datetime": 1787344082,
                "headline": "Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK"
              },
              {
                "id": 141278037,
                "url": "https://finnhub.io/api/news?id=2171816a642cf2107b69f459ff8b534241a7636c5e34d5621c3285981f97c7b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.",
                "category": "company",
                "datetime": 1787338129,
                "headline": "Most Of What Moves AbbVie Stock Has Nothing To Do With The Market"
              },
              {
                "id": 141278407,
                "url": "https://finnhub.io/api/news?id=d2ae63aea5848dbdb0dc5c06d23db65d6bf8f8dc67b166696e8cd91b37bc9c48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.",
                "category": "company",
                "datetime": 1787328060,
                "headline": "Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?"
              },
              {
                "id": 141278408,
                "url": "https://finnhub.io/api/news?id=2ddaa36f268f9adaf00de0f198d3373105e8c7d625ebfb78af1ff712f151bdcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.",
                "category": "company",
                "datetime": 1787327520,
                "headline": "JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know"
              },
              {
                "id": 141278031,
                "url": "https://finnhub.io/api/news?id=cb80cfe11718f7fa6c24e780b8257839be017667ee47bddcd716bbc3e46f2696",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.",
                "category": "company",
                "datetime": 1787308200,
                "headline": "Shareholder pressures Capricor; Lilly dives deeper into vaccines"
              },
              {
                "id": 141279357,
                "url": "https://finnhub.io/api/news?id=55cb96f09a1e590f85001a3921e51a5c2198fd0e168cd1b5b8a9ab8cb0b7b818",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (NYSE:BMY) announced a new collaboration with Chai Discovery to advance AI driven therapeutic antibody discovery. The agreement focuses on using artificial intelligence and machine learning to support the identification of novel therapeutic antibody candidates. The move reflects Bristol Myers Squibb's effort to integrate advanced computational tools into its drug discovery work. This type of AI focused drug discovery effort is gaining traction across biopharma, so it...",
                "category": "company",
                "datetime": 1787281785,
                "headline": "What Could Bristol Myers Squibb (BMY) AI Antibody Deal Mean For Drug Discovery?"
              },
              {
                "id": 141278041,
                "url": "https://finnhub.io/api/news?id=b6b8b6bb83ce7842471b2d3ff17fd226a74f65641d1cab1c940ba182d5fc7a99",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.",
                "category": "company",
                "datetime": 1787250436,
                "headline": "Merck Stock Ran On A Checklist Published In Advance"
              },
              {
                "id": 141278042,
                "url": "https://finnhub.io/api/news?id=a185f67366da2df6e04ff21b866c03090a3bb454dfce33b84acf2978013b48e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.",
                "category": "company",
                "datetime": 1787248494,
                "headline": "Pfizer Stock Is A Race Between New Drugs And Old Patents"
              },
              {
                "id": 141279368,
                "url": "https://finnhub.io/api/news?id=feac3377d2d37a0996cf499205241b049d77bbefd7d8af71c9f5de63a06726bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.",
                "category": "company",
                "datetime": 1787242680,
                "headline": "Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?"
              },
              {
                "id": 141279369,
                "url": "https://finnhub.io/api/news?id=5afbf99a179dd83a0663841a4ff1e28293af44632fd9ab6ef01f990c4554bfbb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.",
                "category": "company",
                "datetime": 1787242440,
                "headline": "Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?"
              },
              {
                "id": 141278139,
                "url": "https://finnhub.io/api/news?id=fcd332a3e0e30fe8a0f7d63cb0a926be225e4bb853171cc00071bc6cf71d34d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.",
                "category": "company",
                "datetime": 1787240431,
                "headline": "Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO"
              },
              {
                "id": 141279358,
                "url": "https://finnhub.io/api/news?id=964b68ef989beb95af6d10dab1e08d5efea4b5ddb7a2d26fb196b6393c1e37ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "SAN FRANCISCO, August 20, 2026--Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery",
                "category": "company",
                "datetime": 1787234400,
                "headline": "Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery"
              },
              {
                "id": 141279359,
                "url": "https://finnhub.io/api/news?id=35b4d8764e8d24f203df2bad71d00c4e99515868c86335980fcf09fd722b62bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "With markets coming in to a volatile time of year, investors might be more interested in generating income rather than capital gains.",
                "category": "company",
                "datetime": 1787227202,
                "headline": "Turn Bristol-Myers Squibb into an Income Machine with This Options Play"
              },
              {
                "id": 141263972,
                "url": "https://finnhub.io/api/news?id=c214f7edde73e38268c28f3292e33e368242c402dff0bce82285ce82ed18e751",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.",
                "category": "company",
                "datetime": 1787223588,
                "headline": "Why Is Merck Stock Still Undervalued After An 80% Surge?"
              },
              {
                "id": 141261028,
                "url": "https://finnhub.io/api/news?id=5b54ec56dfde684c05d3723c87da63c116166a04b8bff3d3ea948663950358c1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2280454849/image_2280454849.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. Learn more about TEM stock here.",
                "category": "company",
                "datetime": 1787212800,
                "headline": "Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance"
              },
              {
                "id": 141278141,
                "url": "https://finnhub.io/api/news?id=f9a21b5be4efd6c3499dc4de20ff1853c616d3d46fa5e2c4daf0a6b0846d3792",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.",
                "category": "company",
                "datetime": 1787172052,
                "headline": "Is AbbVie Stock About To Break Out Again?"
              },
              {
                "id": 141265995,
                "url": "https://finnhub.io/api/news?id=a09e705253ae4293fdf6ecf746da7cdb49428c2a227784546add95ddd0d1e192",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.",
                "category": "company",
                "datetime": 1787169120,
                "headline": "Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?"
              },
              {
                "id": 141279360,
                "url": "https://finnhub.io/api/news?id=0ef8ef77262c5e33cb65bf04229684b4762b0e9d7952b45f784b5506a23bbae4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma",
                "category": "company",
                "datetime": 1787146320,
                "headline": "Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma"
              },
              {
                "id": 141259612,
                "url": "https://finnhub.io/api/news?id=eb433a9b2a9976b0ad3f07e57f713b47285437b7556fb427b093dcffde468d35",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.",
                "category": "company",
                "datetime": 1787145022,
                "headline": "Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play"
              },
              {
                "id": 141253313,
                "url": "https://finnhub.io/api/news?id=2e1130e90380ab9807504bf240b0038a51a19924cdacc932dd13f4834b335bfb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688769969/image_1688769969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio insights on BMY and AZN stock.",
                "category": "company",
                "datetime": 1787131330,
                "headline": "AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?"
              },
              {
                "id": 141244204,
                "url": "https://finnhub.io/api/news?id=e6bf7b78e031bbcb468b8823cda499b666ece9ead74075c85b9647263cd0d6bf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2255337276/image_2255337276.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Rose's Income Portfolio yielding 5.6% reached an all-time value high for the third time in July and is up 12.11% YTD. Read more on the portfolio here.",
                "category": "company",
                "datetime": 1787020480,
                "headline": "5 Undervalued Winners Up To 6.8% And 15 Overvalued To Avoid Now"
              },
              {
                "id": 141217737,
                "url": "https://finnhub.io/api/news?id=6820c078b6e54fa4209864376be3883485e28cbbb76228e7459a6e3b45b80c7b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2264331188/image_2264331188.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Adicet Bio trades below cash ahead of a pivotal 3Q 2026 lupus nephritis CAR-T readout. Click here to read more about the ACET stock.",
                "category": "company",
                "datetime": 1786713485,
                "headline": "Adicet Bio: A Cheap Gamma Delta T-Cell Play"
              },
              {
                "id": 141225151,
                "url": "https://finnhub.io/api/news?id=9853ed06310457ce91e373df0edeacec102984797f3e90006c94a510a1da6bcc",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/14/Rueil-malmaison--France---August-13--202.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therapy approval.",
                "category": "company",
                "datetime": 1786709237,
                "headline": "Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment"
              },
              {
                "id": 141213602,
                "url": "https://finnhub.io/api/news?id=37ace6aaf9f47ac9aae2f6106e25276cc3374f51a8ccba81ebd7b0c6bb0c402f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "There's a good reason why AstraZeneca tanked when merger rumors hit the Street.",
                "category": "company",
                "datetime": 1786674000,
                "headline": "Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?"
              },
              {
                "id": 141210940,
                "url": "https://finnhub.io/api/news?id=257854918e951e5ba83541ec60b6bae6f3ca6bb6d676c69b835d51f455faa988",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., August 13, 2026--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS",
                "category": "company",
                "datetime": 1786655520,
                "headline": "U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse"
              },
              {
                "id": 141210941,
                "url": "https://finnhub.io/api/news?id=c91fb17b3118b546b046b2541db2195d4585a6c195ebe98b6aea050067a3093a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Atrium Therapeutics, Inc. (Nasdaq: RNA) (\"Atrium,\" \"Atrium Therapeutics,\" or the \"Company\"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Investigational New Drug (IND) application for ATR 1072 and continued achievements under its collaboration with Bristol Myers Squibb (BMS).",
                "category": "company",
                "datetime": 1786653840,
                "headline": "Atrium Therapeutics Reports Second Quarter 2026 Financial Results"
              },
              {
                "id": 141208080,
                "url": "https://finnhub.io/api/news?id=0eec4bc8f86fa82eb79333f30349630ca0153f7fae214c6bfcfdc5395e7258ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "A unanimous 3-judge panel ruled that UMB Bank had standing to represent former Celgene shareholders despite a procedural error in its appointment",
                "category": "company",
                "datetime": 1786643647,
                "headline": "Appeals court revives $6.7B lawsuit against Bristol Myers Squibb"
              },
              {
                "id": 141217062,
                "url": "https://finnhub.io/api/news?id=f2cd666b128d3985c371c9dc154ea5be4c543d513111a0608d1c887ed3f166ef",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ZENBEXUS™ (iberdomide) in combination with daratumumabandhyaluronidase-fihj and dexamethasone (ZDd) for the",
                "category": "company",
                "datetime": 1786641626,
                "headline": "Bristol-Myers Squibb Receives FDA Approval For ZENBEXUS In Combination With Daratumumab And Hyaluronidase-fihj and Dexamethasone For Patients with Multiple Myeloma"
              },
              {
                "id": 141207923,
                "url": "https://finnhub.io/api/news?id=88a90702b18759d550549111dea289f1d88362148d397438d1ad60ef07c20c75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.",
                "category": "company",
                "datetime": 1786637411,
                "headline": "The Sharpest Exchanges From ABBV's Earnings Call"
              },
              {
                "id": 141206541,
                "url": "https://finnhub.io/api/news?id=65f67b5b963908dafc83473cd4922915bf65bafd53a62096d93568da5b51af3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.",
                "category": "company",
                "datetime": 1786629600,
                "headline": "Can Keytruda Sustain Merck's Growth in the Second Half of 2026?"
              },
              {
                "id": 141205451,
                "url": "https://finnhub.io/api/news?id=51f516f429febf28f6c5e79007b051ac660b6822ab9a1b7d2ae3528af49000f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Legal operations and legal department leaders from Mastercard, Meta, Google, Uber, General Motors, U.S. Bank, Capital One and more will help shape the future of outside counsel managementNEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Priori, the legal technology company modernizing outside counsel management and hiring, today announced the members of its 2026–2027 Client Advisory Board (CAB), a group of senior legal operations and legal department leaders who provide strategic guidance on the compa",
                "category": "company",
                "datetime": 1786626000,
                "headline": "Priori Expands Client Advisory Board with New Members from Fortune 500 Corporate Legal Departments"
              },
              {
                "id": 141205602,
                "url": "https://finnhub.io/api/news?id=7eef293a6fc6452038bfc9cbb354a29707be9e396aff3d049a94a766493133ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Atrium Therapeutics, Inc. (Nasdaq: RNA) (\"Atrium,\" \"Atrium Therapeutics\" or the \"Company\"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration.",
                "category": "company",
                "datetime": 1786622400,
                "headline": "Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration"
              },
              {
                "id": 141206370,
                "url": "https://finnhub.io/api/news?id=6d7cb5583922ac37ca6de4a5d2dbe416df3c7d0d5b59dc45ab846c33a1061fc1",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "In the complaint, the Company requests, among other things: a judgment declaring that the Company does not infringe and has not infringed any valid claim of the ’697 patent; a judgment declaring that the claims of the",
                "category": "company",
                "datetime": 1786613724,
                "headline": "Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are Invalid"
              },
              {
                "id": 141208941,
                "url": "https://finnhub.io/api/news?id=5708bf80b33dd6bccd825d71319ac078bb355ec1b2cfa36c01c3fb680a7feaa1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/Artificial-Intelligence-Simplifying-Task.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more human-relevant methods.",
                "category": "company",
                "datetime": 1786595630,
                "headline": "Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’"
              },
              {
                "id": 141206330,
                "url": "https://finnhub.io/api/news?id=b48a49126c69ae7754badde85bb6d7fde33ff1c2762086ba9e2bc250215c8ab7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/3d-Rendering-Of-A-Red-Medical-Capsule-An.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s growing influence in medicine.",
                "category": "company",
                "datetime": 1786574462,
                "headline": "Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'"
              },
              {
                "id": 141200401,
                "url": "https://finnhub.io/api/news?id=9f8326d5bf4c5cc8712afd3a3a64b28f795699272f51d641a706f97680ee3451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.",
                "category": "company",
                "datetime": 1786567769,
                "headline": "How ABBV Stock Moved Away From Its Peer Group"
              },
              {
                "id": 141200512,
                "url": "https://finnhub.io/api/news?id=00bc77a193caee8506d9c2f7e49efdf6fa5f4b117ad9f052361cece75a324ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Management raised its full-year forecast, but the market seems to be asking for more than a higher target.",
                "category": "company",
                "datetime": 1786562251,
                "headline": "Amgen Stock And The Price Of A Promise"
              },
              {
                "id": 141200784,
                "url": "https://finnhub.io/api/news?id=a0f94fad322cade1b1dfddb9e669db562bae82620561c6509b5ce01c01288c55",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.",
                "category": "company",
                "datetime": 1786559760,
                "headline": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?"
              },
              {
                "id": 141201339,
                "url": "https://finnhub.io/api/news?id=7e8a2b879ea3d3cdbae7a267034f3347ee60623615312ae00c185009a6957798",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb recently announced it will invest about US$2.30 billion in a new 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, Texas, expected to support production of small molecules, biologics, and antibody-drug conjugates while creating nearly 500 skilled jobs and about 2,000 construction and indirect roles through 2030. This facility’s flexible, automation-ready design and alignment with the company’s broader US$40.00 billion U.S...",
                "category": "company",
                "datetime": 1786547485,
                "headline": "Is Bristol Myers’ US$2.3 Billion Houston Manufacturing Campus Altering The Investment Case For BMY?"
              },
              {
                "id": 141200407,
                "url": "https://finnhub.io/api/news?id=3d4976f509abb60cfa4a755d78912638903405f4f6f5178c1b363bd7a7279a15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.",
                "category": "company",
                "datetime": 1786546980,
                "headline": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?"
              },
              {
                "id": 141200518,
                "url": "https://finnhub.io/api/news?id=78cd813b9ec063ef31be0d6d0b44ffefcc96b5fa0be5dba40387d36f5497337d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.",
                "category": "company",
                "datetime": 1786539024,
                "headline": "Why Revolution Medicines May Be Big Pharma’s Next Takeover Target"
              },
              {
                "id": 141201346,
                "url": "https://finnhub.io/api/news?id=cdd3f17147a81de3ed822a50b1c4e209e4e1e53679e1d2d1e81e7e133d75c4c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including...",
                "category": "company",
                "datetime": 1786507228,
                "headline": "How AstraZeneca’s $400bn deal unravelled"
              },
              {
                "id": 141201347,
                "url": "https://finnhub.io/api/news?id=bbecb6e8a20f34f8b63a34de5295e83ce8024141159a2d0c8360ae7b1c31e5d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.",
                "category": "company",
                "datetime": 1786502722,
                "headline": "1 Profitable Stock with Impressive Fundamentals and 2 We Avoid"
              },
              {
                "id": 141189366,
                "url": "https://finnhub.io/api/news?id=875b935af433bfa3030edf6eff7cc254c4ffb82289f22197cb75fd2f1a2404bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer sent shareholders a fortune in cash, yet the stock fell far behind the market, forcing a hard question about what all that money truly bought.",
                "category": "company",
                "datetime": 1786484330,
                "headline": "$49 Billion In Payouts, A Lagging Stock: The PFE Trade-Off"
              },
              {
                "id": 141201349,
                "url": "https://finnhub.io/api/news?id=ae9d0a8163ba75ce3d088fd49bfc7b194da418acb9d6c9759a186ea77b358b2f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock’s biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed […]",
                "category": "company",
                "datetime": 1786476885,
                "headline": "AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk"
              },
              {
                "id": 141188458,
                "url": "https://finnhub.io/api/news?id=cfa52dd95c0e0956dc23a7fd90a5ebbd1fcc8aa7a3a64b6149e6d03d18b66535",
                "image": "",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "",
                "category": "company",
                "datetime": 1786471593,
                "headline": "Prime Medicine: An Initial Prognosis"
              },
              {
                "id": 141200527,
                "url": "https://finnhub.io/api/news?id=c26f0c93d5ac13d1ee53f2b75881070c80f4c7f2f90f49190e34322cdd77efa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is whether this momentum can last.",
                "category": "company",
                "datetime": 1786467026,
                "headline": "Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus"
              },
              {
                "id": 141201351,
                "url": "https://finnhub.io/api/news?id=c8af5289c2afccab406b8d5261f74ee78b4307b78f6d7e6d97631f359bc8a09e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BMS will invest $2.3 billion in a 600,000-square-foot Houston manufacturing campus at Generation Park in Houston, Texas.",
                "category": "company",
                "datetime": 1786464202,
                "headline": "BMS Plans $2.3B Houston Manufacturing Campus"
              },
              {
                "id": 141201340,
                "url": "https://finnhub.io/api/news?id=60cec4f80942932b58ec98f504f10922630c41ce45fa27cd487b8ecd56ca1fd1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "This will establish BMS’ in-house manufacturing presence in Texas, adding to its ongoing outlicensing and research partnerships in the state.",
                "category": "company",
                "datetime": 1786447555,
                "headline": "BMS banks on Texas for $2.3bn multi-modal manufacturing facility"
              },
              {
                "id": 141183971,
                "url": "https://finnhub.io/api/news?id=e4c287cbdc846d32459bf189d2db32e7a5889c8eed8899b4255e36ca7c625a24",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132436/image_1359132436.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "The Moat Index gained 3.96%, outperforming the S&P 500 as its lower mega-cap technology exposure and financials tilt paid off.",
                "category": "company",
                "datetime": 1786432380,
                "headline": "Rotation Away From Tech Lifts Moat Index In July"
              },
              {
                "id": 141182444,
                "url": "https://finnhub.io/api/news?id=dfd0ba077654e8fca7bf278e40d49c832e758de2d97bbbcd7e37cc093fee2796",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "During Mad Money’s August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here’s a big theme that right now really only impacts two large companies: pent-up demand for mergers and acquisitions now that the Biden era of overzealous antitrust enforcement has […]",
                "category": "company",
                "datetime": 1786427012,
                "headline": "Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 137,
            "discarded_article_count": 116
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.3,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 3,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 3,
            "vcp_reason": "波幅收縮(10.1%→6.2%)；量縮(v10/v30=0.7)；跌縮量(近10日5日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 10300100,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 7230560,
              "avg_vol_20": 7975870,
              "avg_vol_30": 10300100,
              "range_pct_10": 0.06243137254901945,
              "range_pct_20": 0.08847058823529412,
              "range_pct_30": 0.1005490196078432,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7019893010747469,
              "dist_to_20d_high": 0.07124125874125875,
              "down_shrink_days": 5,
              "breakout_level_20d": 68.64,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6209048361934458
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.1287843137254905,
              "turnoverUsdM": 412.2754575,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BMY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 61.0358,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4.3,
            "take_profit_price": 66.9375,
            "target_multiplier": 1.6,
            "technical_strength": 1.38,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.257568627450981,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.BMY",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 1.3571,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.13
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -121.55
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0868
    },
    "kdj": {
      "d": 40.61,
      "j": -18.09,
      "k": 21.04,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 63.11
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 189886434,
      "recentSlope": 73123.4,
      "previousSlope": 2295900
    },
    "rsi": 41.08,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 68.64,
      "position": "SAR喺價上",
      "distancePct": 7.67,
      "previousTrend": "上升"
    },
    "ma50": 63.283,
    "macd": {
      "macd": 0.505870332868497,
      "trend": "中性偏多",
      "signal": 1.082664322178825,
      "histogram": -0.576793989310328
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 66.1953,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.82,
      "score": 4,
      "avgVolume": 7923743,
      "currentVolume": 6467066
    },
    "derived": {
      "ma20": 66.235,
      "ma50": 63.283,
      "prevClose": 64.41,
      "avgVolume10": 7126147,
      "avgVolume20": 7923743,
      "changePercent": -1.02,
      "avgVolumeForScore": 7923743
    },
    "ma_cross": {
      "ma20": 66.235,
      "ma50": 63.283,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 66.2325,
      "prevMa50": 63.1604,
      "spreadPct": 4.66,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 63.4481,
      "upper": 69.0219,
      "position": "中間"
    },
    "rsi_short": 21.23,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.82
    }
  }
}

{
  "close": 63.75,
  "volume": 6467066,
  "changePercent": -1.02
}